during embryo banking, genetic testing pgt-a (preimplantation genetic testing for aneuploidy) can also be performed. we highly recommend any persons with a known or familial history of a pre-existing genetic condition to undergo preimplantation genetic screening. during the genetic test, the healthy embryos will be biopsied and screened for over 400+ different abnormalities. healthy embryos that pass the genetic testing will be frozen for future use.
pgt-a is a preventative measure used to identify chromosomal abnormalities in the embryo, even if there’s no known evidence of a genetic abnormality in either parent. the procedure screens for chromosomal abnormalities such as deletions or translocations, a defect caused when an individual’s chromosomes are rearranged
each cell should contain 23 pairs of chromosomes, or 46 chromosomes total. pgt-a testing assesses all 23 pairs of chromosomes, including the two sex chromosomes (x and y) that determine the embryo’s sex. pgt-a testing can test to see if there are any extra or missing copies of chromosomes in each embryo. chromosome abnormalities are responsible for 60% of miscarriages.
your age plays a critical role in the health of your eggs. the health of your embryos is largely determined by chromosome abnormalities. abnormalities are unlikely to implant and usually result in miscarriage or disorders. by the time you reach 35, 50% of your eggs are chromosomally normal, by 40 only 10-15% of your eggs are chromosomally normal. we recommend pgt-a screening for any women above 35.
pgt-a has been shown to increase success rates of pregnancy, lower miscarriage rates, and avoid any genetic abnormalities. after your embryos are tested the doctor will perform an fet or frozen embryo transfer. it is the same process as regular ivf, only the embryos being transferred have been frozen to undergo testing.
there are over 400 diseases that can be screened out using pgt-a. many abnormalities are caused by single gene mutations inherited from both parents. if both parents are carriers, their chance of having an affected child is 25%. if one parent has the disease their chance of having an affected child is 50%.
a cell biopsy from the tissue that will become the placenta is taken from an embryo for testing.
the test sample is placed in a tube and shipped to a genetic testing lab for analysis. embryos remain at mate fertility and undergo vitrification.
testing results are sent a week later to your provider in a genetic report. your provider will call to discuss the results and next steps.
the embryo(s) with the highest genetic quality are identified and one is transferred to the uterus. the transfer will occur in the following cycle. patients receive medications to optimize the uterine lining and receptivity.